has sponsored live events, journal education, and internet-based CME activities and has awarded more than 80,000 hours of CME credit.Early View from The Oncologist
- An Open‐Label Single‐Arm Phase II Study of Treatment with Neoadjuvant S‐1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus
- Phase II Study of Low‐Dose Afatinib Maintenance Treatment Among Patients with EGFR‐Mutated Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601)
- Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer
- Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
- Clinical Impact of Plasma and Tissue Next‐Generation Sequencing in Advanced Non‐Small Cell Lung Cancer: A Real‐World Experience
- Cases from the Immune‐Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade Induced Diabetes
- Evolution of Cancer Care in Response to the COVID‐19 Pandemic
- Oncologists' Perspective: When Cancer Encounters COVID‐19
- Pegaspargasecombined with concurrent radiotherapy for early stage extranodal natural killer/T‐cell lymphoma, nasal type: A two‐center phase II study
- Genomic alterations of NTRK, POLE, ERBB2 and MSI status in Chinese colorectal cancers